×
About 27,294 results

ALLMedicine™ Chronic Lymphocytic Leukemia Center

Research & Reviews  12,295 results

Discovery of candidate DNA methylation cancer driver genes.
https://doi.org/10.1158/2159-8290.CD-20-1334
Cancer Discovery; Pan H, Renaud L et. al.

May 11th, 2021 - Epigenetic alterations such as promoter hypermethylation may drive cancer through tumor suppressor genes inactivation. However, we have limited ability to differentiate driver DNA methylation (DNAme) changes from passenger events. We developed DNA...

High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients ...
https://doi.org/10.1016/j.leukres.2021.106604
Leukemia Research; Helaly NA, Esheba NE et. al.

May 9th, 2021 - Determination of Bax/Bcl-2 ratio may be a good predictive tool to recognize chronic lymphocytic leukemia (CLL) patients' outcome and prognosis to decide the time and type of therapy. This prospective study was carried out on 100 patients with newl...

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated ...
https://doi.org/10.1158/1078-0432.CCR-20-4890
Clinical Cancer Research : an Official Journal of the Ame... Brieghel C, Aarup K et. al.

May 8th, 2021 - Purpose: TP53 aberration (TP53 mutation and/or 17p deletion) is the most important predictive marker in chronic lymphocytic leukemia (CLL). While each TP53 aberration is considered an equal prognosticator, the prognostic value of carrying isolated...

see more →

Guidelines  53 results

Addition of Ublituximab to Ibrutinib Appears Safe and Effective for Patients With High-Risk Chronic Lymphocytic Leukemia
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200124/full/

May 12th, 2020 - Although chronic lymphocytic leukemia (CLL) has a relatively high 5-year survival rate (85% for people age 20 and older), effective treatments for advanced disease are still needed. Use of combination or monotherapy Bruton’s tyrosine kinase (BTK) ...

Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192083/
Leukemia Research; Paneesha S

Apr 29th, 2020 - The global pandemic of the novel coronavirus SARS-CoV-2 represents one of the greatest infectious challenges to human health in recent history. At the current time over 3.2 million people have been infected and this has proved fatal in over 230,00...

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia
FDA

Apr 20th, 2020 - The Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic...

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical ...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Feb 5th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/18/2/article-p185.xml
JNCCN Wierda WG,et al

Dec 31st, 2019 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

see more →

Drugs  79 results see all →

Clinicaltrials.gov  13,487 results

Discovery of candidate DNA methylation cancer driver genes.
https://doi.org/10.1158/2159-8290.CD-20-1334
Cancer Discovery; Pan H, Renaud L et. al.

May 11th, 2021 - Epigenetic alterations such as promoter hypermethylation may drive cancer through tumor suppressor genes inactivation. However, we have limited ability to differentiate driver DNA methylation (DNAme) changes from passenger events. We developed DNA...

High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients ...
https://doi.org/10.1016/j.leukres.2021.106604
Leukemia Research; Helaly NA, Esheba NE et. al.

May 9th, 2021 - Determination of Bax/Bcl-2 ratio may be a good predictive tool to recognize chronic lymphocytic leukemia (CLL) patients' outcome and prognosis to decide the time and type of therapy. This prospective study was carried out on 100 patients with newl...

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated ...
https://doi.org/10.1158/1078-0432.CCR-20-4890
Clinical Cancer Research : an Official Journal of the Ame... Brieghel C, Aarup K et. al.

May 8th, 2021 - Purpose: TP53 aberration (TP53 mutation and/or 17p deletion) is the most important predictive marker in chronic lymphocytic leukemia (CLL). While each TP53 aberration is considered an equal prognosticator, the prognostic value of carrying isolated...

see more →

News  1,363 results

Timing Important for COVID Vax in Patients With Blood Cancers
https://www.medscape.com/viewarticle/949723

Apr 21st, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. More evidence confirms that antibody-mediated response to COVID vaccination is impaired in patients with blood cancers, but one of the new studies...

GENUINE Improvements: Ublituximab Plus Ibrutinib for CLL
https://www.medscape.com/viewarticle/949633

Apr 19th, 2021 - Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease associated with several known genetic abnormalities, including 17p deletion (del[17p]), 11q deletion (del[11q]), and TP53 gene mutations, which are adverse prognostic markers...

EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma
https://www.medscape.com/viewarticle/948269

Mar 28th, 2021 - European Union approval has been recommended for duvelisib (Copiktra) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or refractory follicular lymphoma (FL) who have received at least two prior lines of therapy. The Europe...

New BTK Inhibitor Pirtobrutinib Shows Promise in CLL
https://www.medscape.com/viewarticle/947440

Mar 14th, 2021 - Pirtobrutinib treatment yielded promising outcomes in chronic lymphocytic leukemia (CLL) and other patients with B-cell malignancies who discontinued prior Bruton's tyrosine kinase (BTK)–inhibitor treatment due to resistance or intolerance, accord...

Experts Offer Roadmap for Treating CLL During the Pandemic
https://www.medscape.com/viewarticle/943140

Dec 22nd, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. COVID-19 has thrown a wrench in standard treatment protocols for patients with chronic lymphocytic leukemia (CLL). These patients already face a g...

see more →

Patient Education  17 results see all →